bioAffinity Technologies, Inc.
BIAFNASDAQHealthcare● Active
$1.59
$-0.01(-0.59%)
Market Cap$7213221
P/E Ratio—
52W High$13.8
52W Low$0.693
bioAffinity Technologies, Inc. (BIAF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BIAF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
-$0.81
Est. -$2.40 · +66.3%
Revenue
$0.00B
Est. $0.00B · -8.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 3-Quarter EPS Beat Streak
BIAF reports quarterly as a NASDAQ-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 19, 2026 | -$2.10 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 8, 2026 | -$2.40 | -$0.81 | +66.3% | $0.00B | $0.00B | -8.9% |
| ▲ Q1 FY2026 | Mar 13, 2026 | -$2.70 | -$1.11 | +58.9% | $0.00B | $0.00B | +2.5% |
| — Q4 FY2025 | Nov 14, 2025 | -$2.70 | -$2.70 | +0.0% | $0.00B | $0.00B | +2.5% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$2.70 | -$3.90 | -44.4% | $0.00B | $0.00B | -10.0% |
| — Q2 FY2025 | May 15, 2025 | -$0.16 | -$0.16 | +0.0% | $0.00B | $0.00B | +53.7% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -$0.14 | -$0.21 | -50.0% | $0.00B | $0.00B | -8.7% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.15 | -$0.16 | -6.7% | $0.00B | $0.00B | -7.4% |
Q3 FY2026
Aug 19, 2026
EPS Actual
—
EPS Est.
-$2.10
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026Beat
EPS Actual
-$0.81
EPS Est.
-$2.40
EPS Surpr.
+66.3%
Revenue
$0.00B
Q1 FY2026
Mar 13, 2026Beat
EPS Actual
-$1.11
EPS Est.
-$2.70
EPS Surpr.
+58.9%
Revenue
$0.00B
Q4 FY2025
Nov 14, 2025
EPS Actual
-$2.70
EPS Est.
-$2.70
EPS Surpr.
+0.0%
Revenue
$0.00B
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$3.90
EPS Est.
-$2.70
EPS Surpr.
-44.4%
Revenue
$0.00B
Q2 FY2025
May 15, 2025
EPS Actual
-$0.16
EPS Est.
-$0.16
EPS Surpr.
+0.0%
Revenue
$0.00B
Q1 FY2025
Mar 31, 2025Miss
EPS Actual
-$0.21
EPS Est.
-$0.14
EPS Surpr.
-50.0%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$0.16
EPS Est.
-$0.15
EPS Surpr.
-6.7%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-1.80 | $-1.80 | $-1.80 | 1 |
| Q3 FY2026 | $-2.10 | $-2.10 | $-2.10 | 1 |
| Q2 FY2026 | $-2.10 | $-2.10 | $-2.10 | 1 |
| Q1 FY2026 | $-2.40 | $-2.40 | $-2.40 | 1 |
| Q4 FY2025 | $-2.70 | $-2.70 | $-2.70 | 1 |
| Q3 FY2025 | $-2.70 | $-2.70 | $-2.70 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 8, 2026 | +66.3% | $2.12 | $2.03 | -4.25% |
| ▲ Q1 FY2026 | Mar 13, 2026 | +58.9% | $1.07 | $2.12 | +98.13% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +0.0% | $1.88 | $1.84 | -2.13% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -44.4% | $8.40 | $7.66 | -8.81% |
| ▲ Q2 FY2025 | May 15, 2025 | +0.0% | $6.75 | $6.17 | -8.59% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -50.0% | $7.86 | $7.80 | -0.76% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -6.7% | $38.70 | $39.90 | +3.10% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -11.8% | $51.60 | $53.40 | +3.49% |
Q2 FY2026-4.25%
Report Date
May 8, 2026
EPS Beat/Miss
+66.3%
Price Before
$2.12
Price After
$2.03
Q1 FY2026+98.13%
Report Date
Mar 13, 2026
EPS Beat/Miss
+58.9%
Price Before
$1.07
Price After
$2.12
Q4 FY2025-2.13%
Report Date
Nov 14, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.88
Price After
$1.84
Q3 FY2025-8.81%
Report Date
Aug 14, 2025
EPS Beat/Miss
-44.4%
Price Before
$8.40
Price After
$7.66
Q2 FY2025-8.59%
Report Date
May 15, 2025
EPS Beat/Miss
+0.0%
Price Before
$6.75
Price After
$6.17
Q1 FY2025-0.76%
Report Date
Mar 31, 2025
EPS Beat/Miss
-50.0%
Price Before
$7.86
Price After
$7.80
Q4 FY2024+3.10%
Report Date
Nov 14, 2024
EPS Beat/Miss
-6.7%
Price Before
$38.70
Price After
$39.90
Q3 FY2024+3.49%
Report Date
Aug 14, 2024
EPS Beat/Miss
-11.8%
Price Before
$51.60
Price After
$53.40
Avg Beat Reaction+20.79%
Avg Miss Reaction-0.75%
Beat Rate4 / 8 quarters
Largest Move+98.13% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BIAF ends December
bioAffinity Technologies, Inc. (BIAF) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $-0.81 — beating the analyst consensus of $-2.40 by +66.3%. BIAF has beaten EPS estimates for 3 consecutive quarters. The next BIAF earnings date is expected around September 1, 2026.
Each quarter, investors track BIAF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BIAF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BIAF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BIAF earnings · 5 questionsbioAffinity Technologies, Inc.'s next earnings report is expected around September 1, 2026. BIAF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BIAF historically reports after market close (AMC).
BIAF earnings datewhen is BIAF earningsBIAF next earnings datewhen does BIAF report earningsBIAF earnings calendar
▸ Source: FMP · bioAffinity Technologies, Inc. SEC filings · US GAAP · bioAffinity Technologies, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026